Literature DB >> 9282529

Measles vaccine efficacy in India: a review.

J Singh1, K K Datta.   

Abstract

Different workers have used different designs to assess effectiveness of live, further attenuated measles vaccine i.e., seroconversion studies, outbreak investigations, field trials and coverage survey methods. The results were often contradictory. We reanalyzed data from these studies to find out optimum vaccine efficacy (VE) and its determinants in the Indian context. Although nutritional status and sex of the subjects did not affect seroconversion rates, the rates were greater among initially seronegative and older children. Overall seroconversion rates in 9-11 months children ranged between 56 and 96%. Studies showing poor seroconversion had an inadequate sample size and/or technical flaws that detracted from the reliability of results. However, appropriately designed studies demonstrated seroconversion rates of more than 90% in 9-11 months children who were initially seronegative. Since 5-10% of 9-11 months old infants had persistent measles maternal antibody, measles vaccine may be around 85-90% effective in this age group. These results are in agreement with the findings observed in outbreak investigations. These outbreaks fulfilled all the criteria which are considered necessary for optimum estimation of VE in such settings; VE was found to be more than 90% in outbreak settings. Conversely, retrospective coverage surveys grossly under estimated VE (about 60%) which was probably due to misclassification of vaccination status of enrolled children. The surveys were undertaken in areas where immunization records were grossly incomplete and only few mothers retained immunization cards. Unfortunately, VE was also under estimated in field trials which were neither randomized nor blind, and no placebo injections were used in control children; many observations were on record which could explain the under estimation of VE. Reanalysis of data from different types of studies indicates that efficacy of measles vaccine given at 9-11 months of age is of the order of 85-90% in the Indian context.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9282529

Source DB:  PubMed          Journal:  J Commun Dis        ISSN: 0019-5138


  6 in total

Review 1.  Effectiveness of measles vaccination and vitamin A treatment.

Authors:  Christopher R Sudfeld; Ann Marie Navar; Neal A Halsey
Journal:  Int J Epidemiol       Date:  2010-04       Impact factor: 7.196

2.  Cost effectiveness analysis of strategies for child health in developing countries.

Authors:  Tessa Tan-Torres Edejer; Moses Aikins; Robert Black; Lara Wolfson; Raymond Hutubessy; David B Evans
Journal:  BMJ       Date:  2005-11-10

3.  Measles in a hilly hamlet of northern India.

Authors:  Bhavneet Bharti; Sahul Bharti
Journal:  Indian J Pediatr       Date:  2002-12       Impact factor: 1.967

4.  Time to re-think measles vaccination schedule in India.

Authors:  T Jacob John; Valsan P Verghese
Journal:  Indian J Med Res       Date:  2011-09       Impact factor: 2.375

5.  Prevalence of Maternal Measles Antibody and Its Associated Factors among Infants in Coastal Karnataka, India.

Authors:  S Sathiyanarayanan; Pawan Kumar; Chythra R Rao; Arun Kumar; Asha Kamath; Veena Kamath
Journal:  Indian J Community Med       Date:  2020 Jan-Mar

6.  The optimal vaccination strategy to control COVID-19: a modeling study in Wuhan City, China.

Authors:  Ze-Yu Zhao; Yan Niu; Li Luo; Qing-Qing Hu; Tian-Long Yang; Mei-Jie Chu; Qiu-Ping Chen; Zhao Lei; Jia Rui; Cheng-Long Song; Sheng-Nan Lin; Yao Wang; Jing-Wen Xu; Yuan-Zhao Zhu; Xing-Chun Liu; Meng Yang; Jie-Feng Huang; Wei-Kang Liu; Bin Deng; Chan Liu; Zhuo-Yang Li; Pei-Hua Li; Yan-Hua Su; Ben-Hua Zhao; Wen-Long Huang; Roger Frutos; Tian-Mu Chen
Journal:  Infect Dis Poverty       Date:  2021-12-28       Impact factor: 4.520

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.